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ABSTRACT
Objectives: The aim of the study was to investigate the effects of two different vaginal progesterone forms, administered 
for luteal phase support, on pregnancy outcomes in normoresponder women aged < 35, who underwent long agonist 
IVF/ICSI-ET cycles.
Material and methods: A retrospective cohort analysis was designed. Normoresponders with primary infertility, who un-
derwent IVF/ICSI-ET cycles employing GnRH analogue and who received progesterone as either capsule or gel form for LPS 
following a single embryo transfer, were analyzed. The cycles were categorized into two groups: micronized progesterone 
vaginal capsule 600 mg/day (Group 1, n = 78) and progesterone vaginal gel 180 mg/day (Group 2, n = 99). Positive β-hCG, 
clinical pregnancy and ongoing pregnancy rates were analyzed.
Results: Both, demographic and stimulation characteristics were comparable between the groups. No difference was 
observed between the capsule and the gel groups regarding positive β-hCG (33.3% and 28.3%, respectively; p = 0.580), 
clinical pregnancy (26.9% and 22.2%, respectively; p = 0.584), and ongoing pregnancy rates (21.8% and 20.2%, respectively; 
p = 0.942) after treatment completion.
Conclusions: In long agonist IVF/ICSI-ET cycles, positive β-hCG, clinical pregnancy and ongoing pregnancy rates do not 
significantly differ between normoresponder patients receiving micronized progesterone vaginal capsule and those receiv-
ing progesterone vaginal gel for LPS.
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INTRODUCTION
Despite significant advances in contemporary repro-
ductive medicine, the clinical pregnancy rate per embryo 
transferred cannot exceed a certain level. Since the early 
days of in vitro fertilization/intracytoplasmic sperm injection 
(IVF/ICSI), implantation failure has constituted a significant 
proportion of treatment failures and remains the cause of 
considerable psychological and physical burden for the pa-
tients. Luteal-phase deficiency (LPD) is a common problem 
in current assisted reproductive technologies (ARTs) and has 
been described in cycles using pituitary down-regulation 
with gonadotropin releasing hormone agonists (GnRHa), as 
well as in those using GnRH antagonists [1]. Normal luteal 
function is considered to be essential for maintaining preg-
nancy, as indicated in one study where removal of the corpus 
luteum during early pregnancy resulted in complete abor-
tion [2]. Over the years, these results have been supported 
by placebo-controlled trials [1, 3], and it became clear that 
luteal phase support (LPS) had a positive effect on the out-
come of IVF cycles using GnRHa protocols, as well as GnRH 
antagonist [1, 3]. To date, progesterone remains to be the 
treatment of choice although many agents, including hCG, 
progesterone, estradiol and GnRHa, or their combinations, 
have been proposed for luteal support [1, 3–6]. 
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Progesterone, as a complementary part of different IVF 
regimens, is administered for LPS through different routes, 
most commonly by intramuscular injection and vaginal 
insertion. However, due to some major side-effects of in-
tramuscular progesterone injection, including pain, skin 
inflammation and rarely infection, vaginal preparations, 
which are generally well tolerated, have become increasing-
ly popular over time. Additionally, considerable differences 
in the efficacy of diverse forms of vaginal progesterone are 
the cause for concern. Hence, numerous LPS-related issues, 
including the most proper agent, timing, duration and route 
of administration, remain unresolved [7–10].
OBJECTIVES
The aim of the study was to compare pregnancy out-
comes of patients with normal ovarian reserve who re-
ceived either micronized progesterone vaginal capsule 
(600 mg/day) or progesterone vaginal gel (180 mg/day) 
for LPS following IVF/ICSI-ET cycles using long GnRH agonist 
protocol.
MATERIAL AND METHODS
The Institutional Review Board waived the requirements 
for approval of the study and patient consent since it is 
a retrospective assessment of conventionally treated pa-
tients. No intervention was involved beyond routine and 
standard arrangement and treatment, and no patient-identi-
fying information was included. This is a retrospective study 
conducted using the files of patients who were admitted to 
the Assisted Reproduction Department of Zeynep Kamil 
Training and Educational Hospital due to the desire to have 
children, between January 2013 and December 2013. 
The analysis was limited to either the first or the second 
IVF/ICSI cycles using long agonist protocol. Normorespond-
ers, aged 23–35 years, with primary infertility and a body 
mass index (BMI) of 18–28 kg/m2, were included into the 
study. We defined normoresponders as having E2 on the day 
of hCG between 800 and 4000 pg/mL and the number of the 
retrieved oocytes between 4 and 18. Figure 1 demonstrates 
the inclusion and exclusion criteria. After the exclusion of the 
patients described in Figure 1, the final number of 177 cycles 
Figure 1. Flow chart of the study: included and excluded cycles. BMI — body mass index, E2 — estradiol, AFC — antral follicle count
Total IVF-ICSI cycles
N: 1073









Group 1 (n = 78); vaginal capsule, 600 mg/day
Group 2 (n = 99); vaginal gel, 180 mg/day
Exclusion criteria:
 1. 23 ≥ age ≥ 35
 2. BMI* > 28 kg/m2
 3. Infertility duration > 7y
 4. Basal FSH > 10 IU/l
 5. Basal E2 > 75 pg/mL
 6. AFC < 6
 7. Abnormalities assessed by transvaginal ultrasono-
graphy
  a. uterine (broids, adenomyosis, mullerian   
 malformations)
  b. ovarian (endometrioma, polycystic ovaries)
  c. adnexal (hydrosalpinx)
 8. Total gonadotropin requirement > 4500 IU
 9. Previous trials in which ≤ 4 oocytes were retrived
 10. Any signicant systemic disease, endocrine or 
metabolic disorder
 11. Azoospermia
 12. Patients with secondary infertility
 13. IVF/ICSI-ET cycle number ≥ 3
 14. Endometrial thickness on hCG day < 6 mm
 15. E2 on the day of hCG ≥ 4000 pg/ml
 16. Number of retrived oocytes < 4 or > 18
 17. Cycles that yielded no embryo or > 1 embryo for 
transfer
 18. Blastocyst transfer cycles
 19. Cycles with missing patient le data
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was enrolled into the study. Demographic characteristics, 
basal hormone profile values, basal transvaginal ultrasonog-
raphy findings, stimulation characteristics, and treatment 
outcomes were obtained from patient files.
In the classical agonist long protocol, pituitary down-reg-
ulation was performed by triptorelin acetate (Decapeptyl®; 
Ferring Pharmaceuticals A.S.), 0.1 mg/day by the subcutane-
ous route, on day 21 of the previous cycle. GnRHa continued 
until the day of hCG administration to induce ovulation. 
On day 2 of the cycle, transvaginal ultrasonography was 
performed and serum estradiol (E2) concentration was 
measured. Gonadotropin treatment was initiated if no fol-
licles > 10 mm in diameter were observed and the E2 level 
was below 50 pg/mL. The initial gonadotropin dose was 
individualized according to patient age, BMI, ovarian re-
serve determined by antral follicle count and basal follicle 
stimulating hormone (FSH), and experience from previous 
cycles. Serial ultrasonographic control examinations and 
E2 level measurements were done until 3 follicles ≥ 17 mm 
and serum E2 level of > 500 pg/mL were detected. Cho-
riogonadotropin alpha 250 μg s.c. (Ovitrelle®; Merck Serono, 
Turkey) was administered to induce final follicular matura-
tion. Transvaginal ultrasound-guided oocyte retrieval was 
performed 35.5 h after hCG administration. Fertilization was 
assessed at 16–18 h after ICSI and one embryo with the best 
morphological grade was transferred into the uterine cavity 
under ultrasound guidance (GE Logiq Alpha 200). National 
health policy of Turkey allows the transfer of two embryos 
in women over the age of 35 and in those with previous 
recurrent implantation failures. In the absence of the two 
of the above mentioned conditions, the transfer is limited 
to only 1 embryo. Hence, we included only single embryo 
transfer cycles in our study since more than 1 embryo trans-
fers belonged to either women over the age of 35 or those 
with recurrent implantation failures. Biochemical pregnan-
cy was defined as a positive pregnancy test result (β-hCG 
levels > 20 mIU/ml) 12 days after embryo transfer. Clinical 
pregnancy was defined as fetal cardiac activity observed by 
vaginal ultrasonography 4 or 5 weeks after oocyte retrieval 
and ongoing pregnancy was defined as ultrasound check 
of the embryo after 9 weeks of gestation.
Luteal support commenced on the night of oocyte re-
trieval and continued until the day of pregnancy testing. 
Methylprednisolone (Prednol 16 mg tablet®, Mustafa Nevzat, 
Turkey) 16 mg/day, also was given orally to all patients for 
4 days to minimize the potential immune reaction for the 
transferred embryos. If the test was positive, progesterone 
treatment was continued for up 9 weeks of gestation. The 
patients were categorized into two groups according to 
the luteal support treatment: group 1 received 600 mg/day 
micronized progesterone capsule (Progestan® 200 mg, soft 
capsule, Koçak, Tekirdag, Turkey) by the vaginal route in 
three equal doses (Capsule Group), whereas group 2 re-
ceived 90 mg progesterone gel (Crinone 8% gel®, Merck 
Serono, Turkey) by the vaginal route twice daily (Gel Group). 
The groups were compared with regard to their demo-
graphic and stimulation characteristics, as well as treatment 
outcomes.
Statistical analysis
Statistical analyses were performed using the Statistical 
Package for the Social Sciences for Windows 15.0 software 
(SPSS, Chicago, IL., USA). Descriptive statistics were given 
as mean, standard deviation, frequency, and percentage. 
Parametric comparison was done using Student’s t test, 
whereas non-parametric comparison was done with the 
Mann-Whitney U test. Categorical data were evaluated using 
the χ2 test. Statistical significance was defined as p < 0.05.
RESULTS
From January 2013 until December 2013, a total of 
1073 cycles (of 987 patient files) were analyzed. Among 
those, 465 cycles employed GnRH agonist long protocol. 
A total of 177 women who met the inclusion criteria were 
included in the study (Figure 1). Overall, mean age ± stan-
dard deviation (SD) was 30.66 ± 3.12 years (from 24 to 35) 
and 59.9% of the indications for IVF were unexplained in-
fertility. The study population was divided into two groups: 
78 cycles received micronized progesterone vaginal capsule 
600 mg/day (Group 1), and 99 cycles received progesterone 
vaginal gel 180 mg/day (Group 2) for luteal support.
Patient and treatment characteristics such as patient 
age, duration and cause of infertility, antral follicle count 
(AFC) on day 1 (D1), D3 FSH, D3 estradiol, average dose of 
gonadotropin, endometrial thickness on the day of hCG, 
serum E2 level on the day of hCG, total number of oocytes 
retrieved, and the number of fertilized oocytes were simi-
lar in both groups, regardless of the type of progesterone 
supplementation used for luteal support (Tables 1 and 2). 
Demographic characteristics of the groups are present-
ed in Table 1. Accordingly, no significant differences were 
found regarding the duration and causes of infertility, basal 
antral follicle count and basal hormone levels between 
the two groups. Stimulation characteristics and treatment 
outcomes of the cycles are shown in Table 2. There were no 
significant differences in stimulation characteristics such as 
mean total gonadotropin doses, E2 levels on hCG day, total 
number of oocytes, number of fertilized oocyte between 
the groups. Treatment outcomes did not show statistically 
significant differences between the two groups regarding 
the positivity of β-hCG per cycle (33.3% and 28.3%; p = 0.580, 
respectively), the clinical pregnancy rate (26.9% and 22.2%; 
p = 0.584, respectively), and the ongoing pregnancy rate 
(21.8% and 20.2%; p = 0.942, respectively) (Table 2).
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DISCUSSION
Despite considerable advances in the field of assisted 
reproduction technologies, the mechanisms involved in the 
implantation process remain to be fully elucidated. Implan-
tation is the outcome of a synchronized communication of 
a hormonally prepared functional uterus and the blastocyst 
complex [10]. It has long been known that this communi-
cation is impaired in the IVF cycles using down-regulated 
controlled ovarian hyperstimulation (COH), and that it must 
definitely be replaced via the LPS treatment [1, 3, 11–14]. Nu-
merous mechanisms may have their roles in the deterioration 
of the luteal phase physiology in IVF treatment cycles, e.g. the 
blockage of LH release with the negative feedback effect of 
the steroids synthesized secondary to the corpora lutea which 
are numerous, LH suppressive effect of GnRHs, possible early 
developmental effect of short-term supranormal estrogen 
and progesterone levels on the endometrium during the lute-
al phase in the induced cycles, and aspiration of the granulosa 
cells during the oocyte pick-up (OPU) procedure [4, 15–17]. 
To date, various agents including progesterone, hCG, 
estradiol and GnRHa, or their combinations, have been 
proposed to support the luteal phase [1, 3–5]. Despite the 
fact that hCG alone has been reported to be superior to 
progesterone in a limited number of studies [1, 3], it has 
never been popular due to the potential risk of ovarian hy-
perstimulation syndrome (OHSS) [3]. However, the need for 
additional estrogen treatment remained debatable [3, 5, 
18]. Recently, additional GnRHa treatments administered 
along with progesterone have been reported to generate 
better result than progesterone treatment alone [4]. While 
the scientific debate continues, progesterone has become the 
treatment of choice, regardless of the fact that the literature 
offers conflicting data on the optimal route of progesterone 
administration during IVF [1, 3, 6]. Previous studies claimed 
that due to the first passing effect through the liver, oral 
progesterones were the least effective forms, contrary to the 
intramuscular forms, which were reported to be the most 
efficient [19]. Nevertheless, later studies and meta-analyses 
Table 1. Demographic characteristics of the patients in the groups
Capsule Group (n = 78) Gel Group (n = 99) P
Age (years) 30.64 ± 3.15 30.67 ± 3.11 0.957a
Duration of infertility (years) 4.47 ± 1.64 4.46 ± 1.78 0.971a
Number of antral follicles on day 1 12.42 ± 3.50 12.88 ± 3.52 0.397a
D3 FSH [IU/L] 7.44 ± 1.60 7.22 ± 1.70 0.375a
D3 estradiol [pg/mL] 46.76 ± 13.93 45.32 ± 16.03 0.531a
















Data are presented as mean ± SD and number (percent). aStudent t test, bχ2 test. FSH — follicle stimulating hormone, LH — luteinizing hormone
Table 2. Stimulation characteristics and treatment outcomes of 177 cycles
Capsule Group (n = 78) Gel Group (n = 99) P
Average gonadotropin dose [IU] 2834.04 ± 967.90 2696.59 ± 1024.8 0.365a
Endometrial thickness on the day of hCG [mm] 9.74 ± 1.79 9.75 ± 1.87 0.989a
E2 on the day of hCG [pg/mL] 1967.72 ± 756.54 2071.62 ± 830.63 0.392a
Number of total oocytes retrieved 8.46 ± 3.78 8.15 ± 3.56 0.591a
Number of MII oocytes 6.46 ± 3.28 6.08 ± 2.97 0.445a
MII oocytes/total oocytes retrieved (%) 76.4% 73.8% 0.311b
Number of the fertilized oocytes 3.90 ± 2.35 3.81 ± 2.08 0.785a
ET day 2.56 ± 0.50 2.57 ± 0.52 0.814a
Positivity rate of β-hCG/cycle (%) 33.3% 28.3% 0.580b
Clinical pregnancy rate/cycle (%) 26.9% 22.2% 0.584b
Ongoing pregnancy rate/cycle (%) 21.8% 20.2% 0.942b
Data are presented as mean ± SD and number (percent). aStudent t test, bχ2 test. FSH — follicle stimulating hormone, hCG — human chorionic gonadotropin, 
E2 — estradiol, ET — embryo transfer
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suggested that there were no differences between the two 
[3, 20, 21]. A recent randomized controlled trial comparing 
the efficacy of subcutaneous and vaginal progesterone 
forms reported that positive β-hCG, clinical pregnancy and 
take-home baby rates were comparable between the groups 
[22]. In a prospective study by Silverberg et al. [23], live birth 
rates were reported to be higher in the vaginal progesterone 
group than in intramuscular progesterone arm. Dose-related 
studies on progesterone have remained limited in number 
and the question whether utilization of different doses of 
progesterone fosters a significant effect on clinical pregnancy 
rates has not yet been fully clarified [3]. Besides, the timing of 
initiation and discontinuation of LPS treatment has also not 
been thoroughly researched yet. To the best of our knowl-
edge, there is only one study dealing with the initiation time 
of the treatment. It suggested that initiating LPS treatment on 
either hCG day, oocyte retrieval day or embryo transfer day 
makes no difference as far as the ongoing pregnancy rates 
are concerned (respectively 20.8%, 22.7% and 23.6%) [7]. 
The general global approach to LPS in IVF treatments 
has been to use vaginal progesterone, particularly vaginal 
gel, due to its minimal side-effect spectrum and ease of 
application [24–28]. However, studies comparing different 
vaginal progesterone formulations with regard to IVF suc-
cess did not go beyond a limited number [24–30]. Detailed 
analysis of the available literature revealed a very limited 
number of studies investigating the differences of the vagi-
nal forms, except for two recent large randomized trials [28, 
30]. Furthermore, except for the work of Stadtmauer et al. 
[30], no study provided live birth rates and none had suf-
ficient power to distinguish whether any difference between 
the varying doses and formulations existed. Two recent 
comprehensive studies provided solid evidence that there 
were no differences between the vaginal gel and vaginal 
ring or tablet groups regarding the clinical pregnancy rates, 
ongoing pregnancy rates, or live birth rates [28, 30].
In the present study, we investigated whether pregnan-
cy outcomes differ between two different vaginal progester-
one formulations which were started on the night of oocyte 
retrieval for LPS, in normoresponders aged ≤ 35 years, un-
dergoing a fresh, single embryo transfer using GnRH agonist 
for ovarian stimulation. Our study results revealed no dif-
ferences between the groups receiving micronized vaginal 
progesterone capsule 600 mg/day and vaginal progester-
one gel 180 mg/day with regard to biochemical pregnancy 
(33.3 and 28.3, p = 0.580, respectively), clinical pregnancy 
(26.9 and 22.2, p = 0.584, respectively) and ongoing preg-
nancy (21.8 and 20.2, p = 0.942, respectively) rates. These 
results are consistent with the previously published reports 
comparing vaginal capsules and gel. 
The comparison of two populations similar to each 
other in terms of basic patient characteristics is one of the 
strengths of our study. The exclusion and inclusion criteria 
were defined so strictly that the patients included were 
limited to a rather narrow spectrum. Our study is subject to 
several limitations, e.g. its retrospective design, small sample 
size, and lack of data on live birth rates. 
CONCLUSIONS
Based on our findings, we conclude that there were 
no statistically significant differences between the use of 
micronized vaginal progesterone 600 mg/day and vaginal 
gel 180 mg/day for LPS treatment, in terms of positivity of 
β-hCG per cycles, the clinical pregnancy rate, and the ongo-
ing pregnancy rate, in normoresponder women undergoing 
long agonist IVF/ICSI cycles. More comprehensive, prospec-
tive, multi-arm, randomized studies are required in order to 
better define the optimum daily drug doses, administration 
route, as well as the initiation and cessation time of the drug. 
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